Results 111 to 120 of about 83,600 (312)

A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.

Journal of Infectious Diseases, 2016
Botulism is a potentially fatal paralytic disease caused by the action of botulinum neurotoxin (BoNT) on nerve cells. There are 7 known serotypes (A-G) of BoNT and up to 40 genetic variants.
S. Maslanka, C. Lúquez, Janet K. Dykes, W. Tepp, Christina L. Pier, Sabine Pellett, Brian H. Raphael, Suzanne R. Kalb, J. Barr, A. Rao, Eric A. Johnson   +10 more
semanticscholar   +1 more source

Therapeutic applications of botulinum neurotoxins in head and neck disorders

Saudi Dental Journal, 2015
Objective: The aim of this article is to review the mechanism of action, physiological effects, and therapeutic applications of botulinum neurotoxins in the head and neck area.
Ahmad Alshadwi, Mohammed Nadershah, Timothy Osborn   +2 more
doaj  

An Ultrasensitive Gold Nanoparticle-based Lateral Flow Test for the Detection of Active Botulinum Neurotoxin Type A

Nanoscale Research Letters, 2017
Botulism is a severe and potentially lethal paralytic disease caused by several botulinum neurotoxin-producing Clostridia spp. In China, the majority of the cases caused by botulism were from less-developed rural areas.
Jing Liu, Shan Gao, Lin Kang, Bin Ji, Wenwen Xin, Jingjing Kang, Ping Li, Jie Gao, Hanbin Wang, Jinglin Wang, Hao Yang   +10 more
doaj   +1 more source

Botulinum Neurotoxin-Producing Bacteria. Isn’t It Time that We Called a Species a Species?

mBio, 2018
Botulinum neurotoxins (BoNTs) are produced by a diverse set of seven clostridial species, though alternate naming systems have developed over the last 100 years. Starting in the 1950s, a single-species taxonomy where any bacterium producing BoNT would be
Theresa J. Smith, C. H. Williamson, K. Hill, J. Sahl, P. Keim   +4 more
semanticscholar   +1 more source

Central Pathophysiology and Brain Network Changes Related to Camptocormia in Parkinson's Disease

Movement Disorders, EarlyView.
ABSTRACT Background Studies on brain connectivity offer important insights into the changes that occur in central network diseases such as Parkinson's disease (PD). Camptocormia, a condition characterized by abnormal flexion of the trunk, often occurs in advanced PD, but its underlying mechanisms are not yet clear.
Tauqeer Anjum, Jan Raethjen, Hao Ding, Nabin Koirala, Rüdiger Pryss, Robin Wolke, Chi Wang Ip, Günther Deuschl, Jens Volkmann, Nils G. Margraf, Muthuraman Muthuraman   +10 more
wiley   +1 more source

Spore Germination Apparatus in Clostridium botulinum Group I and II [PDF]

, 2017
Spore germination is a significant step in the transformation of dormant spores into exponentially dividing vegetative cells, and in the case of Clostridium botulinum in the formation of the deadly botulinum neurotoxin.
Pye, Hannah
core  

Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity [PDF]

, 2006
Purpose: We investigated the effects of BTX-A on visceral afferent nerve transmission by measuring bladder tissue NGF levels in patients with neurogenic detrusor overactivity before and after intravesical treatment with BTX-A.
Bini, V, Di Stasi, SM, Giannantoni, A, Goracci, G, Macchioni, L, Nardicchi, V, Porena, M, Zucchi, A   +7 more
core   +1 more source

Subcutaneous Foslevodopa as Novel Rescue Therapy for Akinetic Crisis in Parkinson's Disease: A Case Report

Movement Disorders Clinical Practice, EarlyView.
Bendix Labeit, Julius Schulten, Alfons Schnitzler, Christian Johannes Hartmann   +3 more
wiley   +1 more source

N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A

Nature Structural &Molecular Biology, 2016
Botulinum neurotoxin serotype A1 (BoNT/A1), a licensed drug widely used for medical and cosmetic applications, exerts its action by invading motoneurons.
G. Yao, Sicai Zhang, S. Mahrhold, K. Lam, D. Stern, K. Bagramyan, K. Perry, M. Kalkum, A. Rummel, M. Dong, Rongsheng Jin   +10 more
semanticscholar   +1 more source

Emerging Opportunities for Serotypes of Botulinum Neurotoxins

Toxins, 2012
Background: Two decades ago, botulinum neurotoxin (BoNT) type A was introduced to the commercial market. Subsequently, the toxin was approved by the FDA to address several neurological syndromes, involving muscle, nerve, and gland hyperactivity.
John Tapia-Núñez, Michael S. Okun, Aparna Wagle Shukla, Ramon L. Rodriguez, J. Glenn Morris, Zhongxing Peng Chen   +5 more
doaj   +1 more source